Mind Medicine (MindMed) Inc
MNMD15.020USD
0.0000.00%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
1.15BValor de mercado
PerdaP/L TTM
Mais detalhes de Mind Medicine (MindMed) Inc Empresa
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Informações de Mind Medicine (MindMed) Inc
Código da empresaMNMD
Nome da EmpresaMind Medicine (MindMed) Inc
Data de listagemMay 04, 2015
CEOBarrow (Robert B)
Número de funcionários74
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 04
EndereçoOne World Trade Center
CidadeNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10007
Telefone12122206633
Sitehttps://ir.mindmed.co/
Código da empresaMNMD
Data de listagemMay 04, 2015
CEOBarrow (Robert B)
Executivos da empresa Mind Medicine (MindMed) Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
198.46K
-25791.00%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
20.08K
-11276.00%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+5402.00%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+5402.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-9234.00%
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Chris Brinzey
Mr. Chris Brinzey
IR Contact Officer
IR Contact Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
198.46K
-25791.00%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
20.08K
-11276.00%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+5402.00%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+5402.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-9234.00%
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: há 3 horas
Atualizado em: há 3 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
5.34%
Commodore Capital LP
3.27%
Driehaus Capital Management, LLC
3.16%
Blackstone Alternative Asset Management, L.P.
2.82%
The Vanguard Group, Inc.
2.61%
Outro
82.80%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
5.34%
Commodore Capital LP
3.27%
Driehaus Capital Management, LLC
3.16%
Blackstone Alternative Asset Management, L.P.
2.82%
The Vanguard Group, Inc.
2.61%
Outro
82.80%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
16.80%
Investment Advisor
13.42%
Hedge Fund
11.26%
Research Firm
1.58%
Individual Investor
1.28%
Private Equity
0.37%
Bank and Trust
0.33%
Pension Fund
0.13%
Venture Capital
0.10%
Outro
54.72%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
415
43.34M
43.99%
-6.62M
2025Q3
385
42.65M
43.29%
-5.82M
2025Q2
380
42.59M
55.97%
-6.05M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
5.26M
5.34%
+38.15K
+0.73%
Sep 30, 2025
Commodore Capital LP
3.23M
3.27%
-1.77M
-35.50%
Sep 30, 2025
Driehaus Capital Management, LLC
3.11M
3.16%
+17.25K
+0.56%
Sep 30, 2025
Blackstone Alternative Asset Management, L.P.
2.78M
2.82%
-810.92K
-22.60%
Sep 30, 2025
The Vanguard Group, Inc.
2.00M
2.03%
+198.88K
+11.04%
Sep 30, 2025
Marshall Wace LLP
2.38M
2.42%
-1.04M
-30.38%
Sep 30, 2025
Octagon Capital Advisors LP
2.13M
2.16%
--
--
Sep 30, 2025
State Street Investment Management (US)
1.92M
1.95%
+119.00K
+6.59%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.82M
1.85%
+91.25K
+5.26%
Sep 30, 2025
Deep Track Capital LP
1.50M
1.52%
-1.00M
-40.00%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
AdvisorShares Psychedelics ETF
9.95%
State Street SPDR S&P Pharmaceuticals ETF
2.17%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.54%
Virtus LifeSci Biotech Clinical Trials ETF
1.32%
iShares U.S. Pharmaceuticals ETF
0.4%
iShares Micro-Cap ETF
0.21%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
Nuveen ESG Small-Cap ETF
0.08%
iShares ESG Aware MSCI USA Small-Cap ETF
0.07%
Ver Mais
AdvisorShares Psychedelics ETF
Proporção9.95%
State Street SPDR S&P Pharmaceuticals ETF
Proporção2.17%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.54%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.32%
iShares U.S. Pharmaceuticals ETF
Proporção0.4%
iShares Micro-Cap ETF
Proporção0.21%
ProShares Ultra Nasdaq Biotechnology
Proporção0.11%
Invesco Nasdaq Biotechnology ETF
Proporção0.11%
Nuveen ESG Small-Cap ETF
Proporção0.08%
iShares ESG Aware MSCI USA Small-Cap ETF
Proporção0.07%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Data
Data ex-dividendo
Tipo
Proporção
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
